arrow
P

Philip C. Mack

ica hn school of medicine at mount sinai
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423–1440]”

勘误表:“国际肺癌研究协会分期项目:常见分子改变对IASLC第九版分期数据库初始分析中NSCLC总生存期的影响”。[胸腔肿瘤学杂志 卷20 期10:1423–1440]

2025-11-010
PRE
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database

国际肺癌研究协会分期项目:在IASLC第九版分期数据库的初步分析中,常见分子改变对非小细胞肺癌总生存期的影响

2025-09-080
PRE
In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients

在COVID-19时期:来自癌症患者研究中的挑战、成功与经验教训

2025-08-010
PRE
State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs
2025-01-010
OA
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

临床干预对肺癌患者SARS-CoV-2免疫的时间依赖性影响

2024-06-261
OAAI
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

多西他赛和曲美替尼治疗KRAS突变阳性复发性非小细胞肺癌 (NSCLC; SWOG S1507,NCT-02642042) 的II期研究

2023-05-264
OA
SeroNet Pooling Project of immunocompromised populations
2023-04-040
PRE
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer
CANCER
IF5.1
2022-12-0925
PRE
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer
2022-09-0711
OAAI
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
2022-06-0255
OAAI
Consensus for HER2 alterations testing in non-small-cell lung cancer

非小细胞肺癌HER2改变检测共识

2022-02-0166
OAAI
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Teisotuzumab Vedotin在c-met阳性IV期或复发性鳞状细胞肺癌患者中的II期研究 (Lung-MAP子研究S1400K,NCT03574753)

2021-05-0153
OAAI